Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCP | P55072 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | DRD4 | P21917 | 2/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.38 |
| ▸ | GRM5 | P41594 | 2/20 | 0.38 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.37 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.36 |
| ▸ | STK10 | O94804 | 2/20 | 0.36 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5869070 | 0.86 | VCP (0.38) | VCPGSK3BDRD2DRD4DRD3 | |
| SCHEMBL7467152 | 0.82 | ERCC5 (0.50) | GSK3BRAB9ALMNA | |
| SCHEMBL7459196 | 0.80 | MAPK14 (0.48) | GSK3BGRM5KAT6ARAB9A | |
| SCHEMBL7459390 | 0.79 | GSK3B (0.46) | GSK3BGRM5GPR139HDAC3RAB9A | |
| SCHEMBL7465211 | 0.79 | GSK3B (0.40) | VCPGSK3BGRM5HDAC3RAB9A | |
| SCHEMBL7463263 | 0.78 | GPR139 (0.45) | GSK3BHDAC1GRM5GPR139HDAC3 | |
| SCHEMBL5869023 | 0.75 | HDAC1 (0.42) | GSK3BHDAC1GPR139 | |
| SCHEMBL5868787 | 0.75 | HDAC1 (0.42) | GSK3BHDAC1GPR139 | |
| SCHEMBL7700583 | 0.75 | GSK3B (0.43) | GSK3BTRPM4GRM5GPR139HDAC3 | |
| SCHEMBL5869064 | 0.74 | GSK3B (0.39) | GSK3BHDAC1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030092677-A1 | Glutamate receptor antagonists | ADAM GEO (DE) | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092677-A1 | Glutamate receptor antagonists | GRM1, GRM3, GRM2 | VCP 3851/4885GSK3B 4288/4885DRD2 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.